Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | South Korea Biosimilar Pipeline: 11 Biosimilars in Development PhaseSouth Korea targeting 22% of global biosimilar market by 2020.
By: KuicK Research Hanwha, one of the top domestic biotechnology companies in Korea entered the biosimilar industry in 2007 and in 2012 signed a partnership with MSD, the Korean branch of U.S. pharmaceutical company Merck to jointly produce and commercialize HD203, a biosimilar form of the arthritis drug Etanercept. This has led to strong competition between Hanwha and Celtrion, which in future is expected to be beneficial to all stakeholders. Competition has also increased in the Korean biosimilars market owing to the enhancement of patent rights for original drugs leading drug makers to focus on the development of new biopharmaceutical products. The South Korean pharmaceuticals and biosimilars industry is considered to be unique on account of the remarkable government initiative and the government’s involvement in the entire lifecycle of biosimilars. The South Korean government has announced its plans to invest significant amounts for the development of the biosimilars industry so as to make the region occupy 22% in the global pie by 2020. The government also has plans to create a robust platform to provide infrastructure and financial assistance. With the Introduction of the “Biosimilar Regulatory Pathway” in 2009, the local industry received a major boost. Various ministries are involved in providing assistance and support. For Report Sample Contact: Avinash Arora avinash@kuickresearch.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|